In a statement released by the company, Chemours said it "strongly refutes the report by Citron Research" pointing to its "five-point transformation plan" which was launched shortly after it was spun-off from parent company DuPont in July last year.
"[Chemours] may be required to indemnify DuPont based on the separation agreement executed before the creation of Chemours through the spin-off of DuPont Performance Chemicals," the company added, but failed to elaborate further.
"Opteon sounds great, until you realise that it's simply a replacement for R134a, which is also Chemours product, so it's simply a cannibalisation of existing business lines and existing EBITDA*," [Citron] said.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados